| Region: | |
| Category: |
(117 reports matching your criteria)
|
Hypertension Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ...
|
read more...
|
$2,000.00
|
|
Anti-Obesity Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ...
|
read more...
|
$2,000.00
|
|
Osteoporosis Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ...
|
read more...
|
$2,000.00
|
|
Anti-Tumor Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ...
|
read more...
|
$2,000.00
|
|
Lymphoma Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ...
|
read more...
|
$2,000.00
|
|
Central Nervous System Disorder Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. ...
|
read more...
|
$2,000.00
|
|
Mental Illness Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ...
|
read more...
|
$2,000.00
|
|
Blood Disease Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ...
|
read more...
|
$2,000.00
|
|
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022
4/30/2013 | published by: GlobalData
... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ...
|
read more...
|
$4,995.00
|
|
Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan
4/1/2013 | published by: PMR
... huge role in supporting the pharmaceutical industry. Meanwhile, the effects of programmes such as Russia’s Pharma 2020, Kazakhstan’s GMP initiative and Ukraine’s updated reimbursement structure are visible in the marketplace. How will issues like these ...
|
read more...
|
$2,800.00
|
|
PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
2/28/2013 | published by: GlobalData
... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022
2/28/2013 | published by: GlobalData
... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Osteoporosis - Japan Drug Forecast and Market Analysis to 2022
2/28/2013 | published by: GlobalData
... osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred ...
|
read more...
|
$4,995.00
|
|
Research Report on China’s Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
2/22/2013 | published by: China Research and Intelligence Co., Ltd.
... morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the ...
|
read more...
|
$1,800.00
|
|
PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022
1/31/2013 | published by: GlobalData
... causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: HIV - Japan Drug Forecast and Market Analysis to 2022
1/31/2013 | published by: GlobalData
... causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for ...
|
read more...
|
$4,995.00
|
